Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Cal Gary who wrote (3277)	2/4/2000 1:46:00 AM
From: jef saunders	Respond to of 14101

i ran charts tonight and the magnitude of the move was astounding. my wife and i are in progress of downing a bottle of champagne, wanted to share the moment ! there was a resistance trendline at 6.05 that had been broken, now that does become a candidate for a support line. so if that holds i retact my previous statement that the 5.xxs are not over. next support below that is 5.75. i had to back quite a ways to find that one. the next resistance is at 7.30. that's ceiling of the top channel, on the maximum length chart. 1.5 million shares trading...wow. liverbest. jeff s.

To: Cal Gary who wrote (3277)	2/4/2000 1:48:00 AM
From: PlayTheKing	Read Replies (2) \| Respond to of 14101

excellent post Cal Gary...and in only 3 minutes!! you may be right that the general increase in share price may be due to an expected listing on nasdaq. a self-fulfilling prophecy may be occuring. investors anticipate that this will be listed soon so they buy. ohers see it going up so they buy!! here is how management has increased the awareness of DMX over the past year: - jnj announcement in may of 1999; (gets investors excited) - the little downturn in july/august when this stock dipped below $3.00 (i got partially kicked out on margin call) - Princess Margaret Hospital "cure"; (got me excited!! - i actually sold all my shares and bought them all back within the next few weeks) - rebecca does the dow jones interview; - world aids conference in geneva; - wayne gretzky commercial (quite short-lived IMO) - the recent offering of $10M secondary offering and having HSBC as the underwriter; (this increases institutional awareness); - road show to the U.S. by Peter? have i missed anything? i'm sure i did. in any case, word is getting out there about this company... it's been a long wait but we are all finally seeing some light at the end of the tunnel. PlayTheKing P.S. why is this posting going off screen?? i gave up trying to fix it..

To: Cal Gary who wrote (3277)	2/4/2000 6:29:00 AM
From: Mark Bartlett	Respond to of 14101

Cal, Excellent summary of QLT vs DMX. The only thing I would add is, at the present (as far as I am aware) QLT's treatment for eyesight loss (maculopapular degneration) is the only one now available. That being said, the market for that area is very small -- about 600 million. DMX's market is far larger with Pennsaid only. Adding the potential for WF10 and the other possible uses for the carrier (onychomycosis and hair loss) and you have a huge potential market. If the onychomycosis* trials work out, that will be pretty much DMX's market, barring no other discoveries elsewhere. MB *For anyone new, this is a hand and nail fungal infection caused by a few different types of fungi. It is presently very hard to kill, ofter requiring prolonged oral anti-fungals with a high recurrence rate.